| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.10% | 66.88% | 63.62% | 59.24% | — | — | — | — | — | — | — | — |
| Operating Margin | 11.17% | 3.62% | -23.76% | -13.85% | -37.31% | -30.12% | -12.57% | -24.16% | -36.88% | -44.25% | -67.60% | -75.95% |
| EBITDA Margin | 15.31% | 8.88% | -16.23% | -5.11% | -28.39% | -23.36% | -9.15% | -19.90% | -31.54% | -38.86% | -63.05% | -72.88% |
| Net Margin | 12.83% | 5.41% | -20.61% | -12.33% | -34.42% | -29.71% | -10.47% | -25.00% | — | — | — | — |
| Current Ratio | 8.15 | 4.73 | 4.66 | 3.97 | 3.79 | 22.39 | 10.74 | 7.42 | 4.48 | 6.38 | 3.26 | 2.53 |
| Quick Ratio | 7.81 | 4.46 | 4.40 | 3.74 | 3.61 | 22.11 | 10.35 | 7.16 | 4.04 | 6.08 | 3.00 | 2.31 |
| Debt / Equity | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.32 | 0.67 | 0.42 | 0.10 | 0.12 |
| ROE | 5.07% | 2.05% | -7.13% | -3.40% | -6.89% | -8.29% | -5.26% | -28.84% | — | — | — | — |
| ROA | 4.72% | 1.86% | -6.67% | -3.16% | -6.36% | -7.64% | -4.58% | -19.06% | — | — | — | — |
| Asset Turnover | 0.37 | 0.34 | 0.32 | 0.26 | 0.18 | 0.26 | 0.44 | 0.76 | 0.91 | 0.64 | 0.66 | 0.59 |
| Book Value / Share | 16.25 | 15.05 | 14.37 | 15.03 | 16.15 | 7.91 | 5.19 | 2.15 | 1.10 | 2.07 | 1.97 | 1.91 |
Veracyte Inc. is a global diagnostics company specializing in advanced genomic tests that provide clinicians with precise insights to diagnose and treat cancer. Its portfolio features key products such as Afirma for thyroid cancer, Decipher Prostate and Decipher Bladder for prostate and bladder cancers respectively, Prosigna for breast cancer, Envisia for interstitial lung diseases including idiopathic pulmonary fibrosis, and Percepta for lung cancer diagnosis. These molecular diagnostics leverage genomic sequencing, machine learning, and clinical data through the company's innovative Veracyte Diagnostics Platform, enabling AI-assisted analysis and evidence generation to support personalized treatment decisions and avoid unnecessary surgeries. Veracyte Inc. operates centralized CLIA labs in the US and offers distributed in vitro diagnostics for international markets across North America, Europe, and the Middle East, serving healthcare providers, biopharmaceutical partners, and biotechnology sectors. Founded in 2006 and headquartered in South San Francisco, California, the company plays a vital role in precision oncology by transforming cancer care with actionable genomic information at critical decision points.